News

Osaka (Japan), April 27, 2023 - Maruho Co., Ltd. ("Maruho", Head Office: Osaka, Japan, President and CEO: Atsushi Sugita) announces that it has entered into a license agreement with Nielsen BioSciences, Inc. ("Nielsen", Head Office: San Diego, California, USA, President and COO: David Burney) for the exclusive rights to market Candida albicans extract (hereinafter referred to as "the compound") in Japan for the treatment of Verruca vulgaris, which is being developed globally in Japan and the U.S.

Under the terms of the agreement, Maruho is granted an exclusive license for the post-launch sales and promotional activities of the compound in Japan after it is developed by Nielsen and approved by regulatory authorities. In addition, Maruho will pay Nielsen an upfront payment and milestone payments based on development and regulatory progress and sales in Japan.

Verruca vulgaris are benign lesions caused by infection of the skin with the human papilloma virus (HPV). They are raised lesions on the skin, commonly on the fingers, palms, knees, and soles of the feet. Because they are caused by a viral infection, skin symptoms can be widespread and refractory.

Maruho aims to further contribute to improving the quality of life for patients by providing a new option for the treatment of Verruca vulgaris, for which there are few treatment options.

Note

The information contained in this news release in regard to pharmaceutical and developmental products is not intended for the purpose of promotion, advertising or medical advice.

About NielsenNielsen BioSciences, Inc. is a privately-held, San Diego-based biopharmaceutical company focused on developing and commercializing biological products with wide-ranging applications in cell-mediated immune responses.
For more information, please visit https://nielsenbio.com/about-us/

About Candida albicans extractThe Candida albicans extract-based skin test antigen is the active ingredient in Nielsen's CANDIN^® (Candida albicans Skin Test Antigen for Cellular Immunity) ("CANDIN^®") product currently marketed in the United States for its U.S. Food and Drug Administration-approved use as a skin test antigen for the assessment of cellular hypersensitivity to Candida albicans. Neither CANDIN^® nor the compound is currently approved in the United States or Japan for the treatment of Verruca vulgaris or any other indications.

About MaruhoMaruho Co., Ltd. has its head office in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,547 employees (as of the end of September 2022), and net sales were approximately 85.67 billion yen in its fiscal year ended September 30, 2022. With the mission "More smiles, brighter life for you.", Maruho aims to help realize a society where everyone can live with a smile. For more information, please visit https://www.maruho.co.jp/english/